Zydus Cadila's net profit leaps 46% in Q4; Orexigen analysts still say 'buy';

@FiercePharma: Japan's MHLW sets Sovaldi price, hep C competition heats up. FiercePharmaAsia article | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing this week: Alexion expanding in Ireland. Will spend $506M on its first biologics plant outside of U.S. Story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Mylan shareholders face big M&A-related taxes, especially if Teva's bid succeeds. Report | Follow @CarlyHFierce

> Zydus Cadila's net profit jumped 46% in Q4, it reported. More

> Analysts who cover Orexigen ($OREX) are almost all saying "buy," despite the company's tumultuous week. Report

> Dr. Reddy's Laboratories ($RDY) has launched stroke-management drug Somazine in India. Report

> A U.S. judge rejected FedEx's ($FDX) bid to dismiss charges it conspired with "rogue" online drugstores. Report

Medical Device News

@FierceMedDev: Swedish asthma diagnostic company Aerocrine to be acquired by biotech Circassia for $214M. More | Follow @FierceMedDev

@VarunSaxena2: Medtronic's leadless pacemaker and MRI-safe defibrillator present positive trial data at cardiology conference. Article | Follow @VarunSaxena2

@EmilyWFierce: OncoCyte ropes in $7M for cancer diagnostic R&D. FierceDiagnostics story | Follow @EmilyWFierce

> Data presented at cardiology conference show Abbott's MitraClip can cut arrhythmias in half. More

> Medtronic's leadless pacemaker and MRI-safe defibrillator present positive trial data at cardiology conference. Report

> Swedish asthma diagnostic company Aerocrine to be acquired by biotech Circassia for $214M. Article

Biotech News

@FierceBiotech: Special report: The 25 most influential people in biopharma in 2015. Feature | Follow @FierceBiotech

@JohnCFierce: Circassia snags a pair of asthma biotechs for $376M. Report | Follow @JohnCFierce

@DamianFierce: Wait did they just invent NantPharma for this deal? Is there a geneology chart for the NantFamily? Release | Follow @DamianFierce

> Soon-Shiong bets $90M on Sorrento's next-gen Abraxane with $1.2B on the line. Report

> Celladon halves its workforce to conserve cash after gene therapy meltdown. Story

> Racing a crowded field, Amgen says migraine drug looks promising in PhII. Article

And Finally... London's King's College Hospital is piloting a scheme whereby cancer patients undergoing chemotherapy treatments are given Apple Watches to manage their medication. More

Suggested Articles

Merck’s Keytruda went up against chemo in a head-to-head colorectal cancer battle—and won.

While the FDA gave an emergency green light to chloroquine's use against coronavirus, European regulators are restricting the drug to clinical trials.

Biocon has finally satisfied the FDA that its insulin production plant in Malaysia is ready for prime time.